The University of Pittsburgh's Cardiovascular Gene Therapy Center has been designated as the only national facility for producing vectors for use in clinical trials funded by the National Heart, Lung and Blood Institute. The NHLBI's move is likely to create a backlog of academic products awaiting clinical development. As a result, biotech and pharma companies may enjoy an increase in licensing opportunities from institutions whose compounds are far